Adapting In Vivo Chemosensitivity for Further Evaluation of Preoperative Chemotherapy in Patients with Operable Primary Breast Cancer. Interim Analysis of the GEPR-TRIO Trial

Jackisch C,1 von Minckwitz G,2 Blohmer JU,3 Löhr A,4 Raab G,5 Gerber B,6 Eidtmann H,7 Hilfrich J,8 Costa SD,9 Kaufmann M,2 for the German Breast Group (GBG; www.germanbreastgroup.de)

INTRODUCTION

The main objective of neoadjuvant therapy for breast cancer is downstaging of the primary tumor prior to surgical resection. This will lead to lower surgical margins, better local control of disease, and improved long-term survival. The present study, which has been reported previously, demonstrated that a neoadjuvant dose-dense schedule of docetaxel–doxorubicin (once every 3 weeks) is superior to the standard neoadjuvant salvage regimen (vinorelbine–capecitabine). The results of this study highlight that different regimens may improve the clinical response rate and local recurrence rate in patients with breast cancer. The present study was conducted at the German Breast Group (GBG) and 1105 patients were included. The study was conducted in 2001, and a total of 1105 patients were included in the study.

METHODS

Main inclusion criteria

- Histologically confirmed invasive ductal carcinoma
- Positively selected invasive breast cancer
- Adequate hepatic, renal, and cardiac function
- Written informed consent

RESULTS: GEPR-TRIO (PHASE II–III STUDY)

CONCLUSIONS

- The present study is the largest randomized trial performed in breast cancer patients.
- The study was conducted in 1105 patients and demonstrated that a neoadjuvant dose-dense schedule of docetaxel–doxorubicin (once every 3 weeks) is superior to the standard neoadjuvant salvage regimen (vinorelbine–capecitabine).
- The results of this study highlight that different regimens may improve the clinical response rate and local recurrence rate in patients with breast cancer.

OBJECTIVES

- Primary objective
- Secondary objectives

RESULTS

- Baseline patient and tumor characteristics (n=1105)
- Table 1: Baseline patient and tumor characteristics (n=1105)
- Table 2: Baseline patient and tumor characteristics (n=1105)
- Table 3: Summary of patient data
- Table 4: Summary of patient data
- Table 5: Summary of patient data

CONCLUSIONS

- The present study is the largest randomized trial performed in breast cancer patients.
- The study was conducted in 1105 patients and demonstrated that a neoadjuvant dose-dense schedule of docetaxel–doxorubicin (once every 3 weeks) is superior to the standard neoadjuvant salvage regimen (vinorelbine–capecitabine).
- The results of this study highlight that different regimens may improve the clinical response rate and local recurrence rate in patients with breast cancer.